Pitt Street Research Interviews CEO Steven Lydeamore
Brisbane, April 16, 2019 AEST (ABN Newswire) - While in Sydney earlier this month, Anatara Lifesciences (
ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.
Stuart spoke with Steve about the path to market for the Company's new gastrointestinal reprogramming dietary supplement product, called GaRP.
Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.
To view the interview, please visit:
http://www.abnnewswire.net/lnk/I42H84NZ
To view the latest Corporate Fact Sheet for further information on Anatara Lifesciences, please visit:
http://abnnewswire.net/lnk/G465OU6A
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
